Pharmafile Logo

biotherapeutics

- PMLiVE

Pharma-Exclusive Webinar: Redefining Engagement in the AI Era

Join Impetus Digital's pharma-exclusive webinar to discover how compliant AI tools and virtual workflows can elevate static programs into high-retention, interactive experiences without enterprise overhead.

Impetus Digital

- PMLiVE

NEW PHARMA-EXCLUSIVE WEBINAR: Beyond the Hype; Practical, Compliant AI Solutions for Pharma Engagement

See how top-tier pharma teams use compliant AI tools and virtual QIPs to capture real-time market intelligence, confidence scores, and audience insights from live dashboards

Impetus Digital

- PMLiVE

Sanofi announces phase 3 study data for infantile-onset Pompe disease

Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form

- PMLiVE

Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses

SPMS is a debilitating stage of MS where patients experience increasing levels of disability

- PMLiVE

Sanofi appoints Paulo Fontoura as Global Head of R&D

Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche

- PMLiVE

Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector

It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma

- PMLiVE

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

The treatment can be used to delay the onset of clinical type 1 diabetes

- PMLiVE

HRW Wins 2026 Artificial Intelligence Excellence Award in the Pharmaceutical Category

Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....

Healthcare Research Worldwide

- PMLiVE

Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education

See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.

Impetus Digital

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links